Casaasdas

Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor

Por um escritor misterioso
Last updated 30 março 2025
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Disease Activity Cutoff Values in Initiating Tumor Necrosis Factor
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Recommendations by the Spanish Society of Rheumatology on the Use
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Subanalysis of predictors of clinical remission achievement during
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
ASAS20/40 response rates and mean change from baseline in BASDAI
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Microvascular dysfunction in ankylosing spondylitis is associated
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Frontiers Leveraging the tolerogenic potential of TNF-α and
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Evaluation of anti-TNF therapeutic response in patients with
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Long-Term Adherence to Etanercept in Treatment Effectiveness of
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
ASAS-EULAR recommendations for the management of axial
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
Frontiers The Clinical and MRI Effect of TNF-α Inhibitors in
Changes of disease activity [(a) ASDAS; (b) BASDAI] for TNF-α inhibitor
TNF Inhibitor Therapy, Ankylosing Spondylitis
Recomendado para você
você pode gostar

© 2014-2025 progresstn.com. All rights reserved.